Celularity Inc. announced the US FDA has granted Orphan Drug Designation for its investigational natural killer cell therapy, CYNK-101, for treatment of gastric/gastroesophageal junction cancer.
[Celularity Inc.]
Sorry, but the selected Zotpress account can't be found.